Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PGD | P52209 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325113 | 1.00 | MAPK1 (0.40) | MAPK1NPSR1PGDCYP2C9ADORA3 | |
| SCHEMBL15326412 | 0.87 | MAPK1 (0.37) | MAPK1NPSR1PGDCA2 | |
| SCHEMBL20091180 | 0.85 | CA2 (0.41) | MAPK1NPSR1PGDCYP2C9ADORA3 | |
| SCHEMBL15326452 | 0.80 | MAPK1 (0.42) | MAPK1NPSR1PGDGAACA2 | |
| SCHEMBL16639434 | 0.77 | — | — | |
| SCHEMBL4396176 | 0.76 | TSHR (0.50) | CYP2C9 | |
| SCHEMBL16640743 | 0.76 | MAPK1 (0.34) | MAPK1NPSR1PGD | |
| SCHEMBL18658568 | 0.76 | MAPK1 (0.34) | MAPK1NPSR1PGD | |
| SCHEMBL15325122 | 0.76 | MAPK1 (0.42) | MAPK1NPSR1PGD | |
| SCHEMBL15326430 | 0.76 | MAPK1 (0.42) | MAPK1NPSR1PGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365573-B2 | Method for synthesizing sapropterin dihydrochloride | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | TIANJIN ASYMCHEM PHARMACEUTICAL CO., LTD (CN) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105555-A1 | METHOD FOR SYNTHESIZING SAPROPTERIN DIHYDROCHLORIDE | CYP51A1, DHCR7, LSS | MAPK1 3539/4885NPSR1 1105/4885PGD 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.